Document is current
Any future updates will be listed below
-
Authors
Lee, Che Yu https://orcid.org/0000-0002-3039-4894
Hwang, Ahyeon
McRiley, Delaney
Lee, Jaywon https://orcid.org/0009-0007-8432-7738
Thibodeau, Genevieve
Duman, Catharine
Zhang, Xiangyu
Skarica, Mario https://orcid.org/0000-0002-2478-014X
Coudriet, Jensine
Xu, Siwei https://orcid.org/0000-0002-2828-3706
Terwilliger, Rosemarie
Sliby, Alexa-Nicole
Wang, Jiawei https://orcid.org/0000-0003-2627-4897
Nguyen, Tuan https://orcid.org/0000-0002-1703-0404
Liu, Yujing
Li, Hongyu https://orcid.org/0000-0001-6525-9310
Dai, Yi https://orcid.org/0009-0004-1018-5931
Duan, Ziheng
Lei, Yutong
Lin, Yingxin https://orcid.org/0000-0002-4299-7326
Glausier, Jill R. https://orcid.org/0000-0001-9838-3414
Lewis, David A. https://orcid.org/0000-0002-3225-6778
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
Holtzheimer, Paul E.
Xu, Ke https://orcid.org/0000-0002-6472-7052
Zhou, Hang https://orcid.org/0000-0002-7694-6391
Zhao, Hongyu https://orcid.org/0000-0003-1195-9607
Thompson, Summer https://orcid.org/0000-0003-1922-1201
Krystal, John H. https://orcid.org/0000-0001-6952-1726
Che, Alicia https://orcid.org/0000-0002-7530-8531
Taylor, Jane R.
Zhang, Jing https://orcid.org/0000-0002-5970-0509
Girgenti, Matthew J. https://orcid.org/0000-0003-1647-326X
-
Funding
Funding for this research was provided by:
Brain and Behavior Research Foundation
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (R01AA031017)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DP1 DA060811)
- License Information
-
More Information
Article History
Received: 6 November 2024
Accepted: 5 January 2026
First Online: 19 January 2026
Competing interests
: J.H.K. has consulting agreements (less than US$10,000 per year) with the following: Aptinyx, Inc. Biogen, Idec, MA, Bionomics, Limited (Australia), Boehringer Ingelheim International, Epiodyne, Inc., EpiVario, Inc., Janssen Research & Development, Jazz Pharmaceuticals, Inc., Otsuka America Pharmaceutical, Inc., Spring Care, Inc., Sunovion Pharmaceuticals, Inc.; is the co-founder for Freedom Biosciences, Inc.; serves on the scientific advisory boards of Biohaven Pharmaceuticals, BioXcel Therapeutics, Inc. (Clinical Advisory Board), Cerevel Therapeutics, LLC, Delix Therapeutics, Inc., Eisai, Inc., EpiVario, Inc., Jazz Pharmaceuticals, Inc., Neumora Therapeutics, Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corporation, PsychoGenics, Inc., Takeda Pharmaceuticals, Tempero Bio, Inc., Terran Biosciences, Inc..; has stock options with Biohaven Pharmaceuticals Medical Sciences, Cartego Therapeutics, Damona Pharmaceuticals, Delix Therapeutics, EpiVario, Inc., Neumora Therapeutics, Inc., Rest Therapeutics, Tempero Bio, Inc., Terran Biosciences, Inc., Tetricus, Inc.; and is editor of Biological Psychiatry with income greater than $10,000. The remaining authors declare no competing interests.
